Efficacy of leukotriene antagonists as concomitant stherapy in allergic rhinitis

Laryngoscope

Volumn 120, Issue 9, 2010, Pages 1718-1723

  Cingi, Cemal ^a   Gunhan, Kivanc ^b   Gage White, Linda ^c   Unlu, Halis ^b  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^b CELAL BAYAR UNIVERSITY   (Turkey)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Allergic rhinitis; Leukotriene receptor antagonist; Leukotrienes; Montelukast

Indexed keywords

FEXOFENADINE; MONTELUKAST; PLACEBO;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NASAL LAVAGE; PATIENT SATISFACTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOMANOMETRY;

ACETATES; ADULT; AIRWAY RESISTANCE; ANTI-ALLERGIC AGENTS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; PAIN MEASUREMENT; PATIENT SATISFACTION; QUINOLINES; RHINITIS, ALLERGIC, PERENNIAL; RHINOMANOMETRY; TERFENADINE; TREATMENT OUTCOME;

EID: 77956605581     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20941     Document Type: Article

References (15)

1. Peters-Golden M, Sampson AP. Cysteinyl leukotriene interactions with other mediators and with glucocorticosteroids during airway inflammation. J Allergy Clin Immunol 2003;111:537-542.
2. Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986;16:289-297.
3. Figueroa DJ, Borish L, Baramki D, Philip G, Austin CP, Evans JF. Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis. Clin Exp Allergy 2003;33:1380-1388.
4. Shirasaki H, Kanaizumi E, Watanabe K, et al. Expression and localization of the cysteinyl leukotriene 1 receptor in human nasal mucosa. Clin Exp Allergy 2002;32:1007-1012.
5. Volovitz B, Osur SL, Bernstein JM, Ogra PL. Leukotriene C4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children. J Allergy Clin Immunol 1988;82:414-418.
6. Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 2005;127:1312-1326.
7. Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy 2000;55:7-16.
8. Bousquet J, Van Cauwenberge P, Khaltaev N; ARIA Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108 (suppl 5):S147-S334.
9. Sebaldt RJ, Sheller JR, Oates JA, Roberts LJ, Fitzgerald GA. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci U S A 1990;87:6974-6978.
10. Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104:927-933.
11. Philip G, Malmstrom K, Hampel FC Jr, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32:1020-1028.
12. Topuz B, Ogmen GG. Montelukast as an adjuvant to main-stay therapies in patients with seasonal allergic rhinitis. Clin Exp Allergy 2003;33:823-826.
13. Okuda M, Watase T, Mezawa A, Liu C. The role of leukotriene D4 in allergic rhinitis. Ann Allergy 1988;60:537-540.
14. Lund VJ. Objective assessment of nasal obstruction. Otolaryngol Clin North Am 1989;22:279-290.
15. Berger WE, Lumry WR, Meltzer EO, Pearlman DS. Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc 2006;27:214-223.